Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab soravtansine plus carboplatin in platinum-sensitive ovarian cancer
NCT05456685Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2022
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by AbbVie Inc.. Started Sep 2022; status: active, not recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05456685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456685.